In the Vasodilator-Heart Failure Trials (V-HeFT-I and VHeFT-II), SCD was the most prominent cause of overall death and accounted for 31% to 44% of deaths, depending on treatment arm randomization. 5 When comparing sudden and pump failure deaths, V-HeFT investigators found that until the fifth year of follow-up, patients were more likely to die from SCD, no matter the treatment arm to which they were randomized. 5 In addition, the presence of couplets also predicted increased mortality. 6 Thus, even when HF is mild to moderate, ventricular dysrhythmias are an important phenomenon that can lead to SCD.
The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) investigators studied SCD death as an endpoint. 7 As in other studies, mortality increased as HF worsened. At 1 year, mortality was 6%, 10.5%, and 18.6% for functional classes II, III, and IV, respectively. When patients were stratified by severity of HF, SCD was greatest in patients in mild HF (functional class II; 64%) and decreased as functional class worsened (functional class III, 59%; and functional class IV, 33%). Thus, while annual mortality of patients with mild HF was less than that of patients with advanced HF, SCD rates were higher. In this study, SCD did not equal death from ventricular tachycardia and fibrillation; rather it reflected a witnessed instantaneous or unwitnessed death without progressive circulatory failure or death within 28 days after resuscitation from cardiac arrest. This study enrolled 3991 patients, but the majority of patients enrolled were in functional class II or III; less than 4% were in functional class IV. 7 The small sample of functional class IV patients and the limited number of deaths in this subgroup could have skewed mode of death results.
Although SCD is recognized as a problem, primary and secondary prevention is a challenge. Prediction of ventricular dysrhythmias can be difficult since they can occur without symptoms, the positive predictive value of many tests is limited, and when dysrhythmias are nonsustained, healthcare providers are challenged to recognize their occurrence. In addition, suppression of nonsustained dysrhythmias is also controversial, even though it is estimated that 80% of ambulatory cardiac patients who had a Holter monitor on at the time of death had a recording of ventricular fibrillation or tachycardia. 8 For example, antidysrhythmic agents may be proarrhythmic, which could increase morbidity and mortality.
Results of ventricular dysrhythmia research on allcause mortality or SCD in patients with HF are conflicting and somewhat contradictory to expectations. For example, when sustained stable ventricular tachycardia (defined as ventricular tachycardia without serious symptoms or hemodynamic compromise) was compared to unstable ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillator (AVID) registry, stable ventricular tachycardia was associated with a nonsignificantly higher mortality rate. 9 The AVID investigators suggested that stable ventricular tachycardia might be a marker for a cardiac electrophysiological substrate that was capable of producing a more malignant dysrhythmia. In patients with advanced HF, defined as NYHA functional class II, III, or IV after adequate medical treatment, an ejection fraction of 35% or less, and a cardiothoracic ratio of greater than 0.55, researchers found that couplets, ventricular repetitive beats, and nonsustained ventricular tachycardia were independent markers of total mortality and SCD. 10 This finding was contradictory to findings from Singh et al, who were unable to demonstrate similar results. 11 In one study of patients with advanced HF and NYHA functional classes II to IV symptoms, presence of nonsustained ventricular tachycardia trended toward all-cause mortality (P = .07) but not toward SCD. 11 Researchers suggested that the presence of ventricular dysrhythmias served as a marker for severe leftventricular dysfunction and that suppression may not improve survival. In another study of patients with advanced HF, asymptomatic premature ventricular beats greater than 30 per hour, couplets, and nonsustained ventricular tachycardia were predictors of all-cause death and SCD on univariate analysis but were nonsignificant by multivariate analysis. 12 The paradoxical results reported above reinforce the notion that the presence of ventricular dysrhythmias may not automatically identify candidates for antidysrhythmic or device therapy. Thus, it is important for nurses to understand the basis for current preventive strategies of SCD. This article reviews ventricular dysrhythmias in patients with HF. Pathophysiological mechanisms and conditions that predispose patients with HF to ventricular dysrhythmias and SCD will be described. Evidence-based management will be discussed. Nurses play an important role in prompting and optimizing care strategies that promote suppression of dysrhythmogenesis and treatment of ventricular dysrhythmias so that the risk of SCD is minimized. Specific nursing actions are highlighted.
Pathophysiological Mechanisms
There are many modulating factors that contribute to ventricular dysrhythmogenesis in HF. There is a complex interplay between the cellular mechanisms in hypertrophied and failing myocardium that cause dysrhythmias, environmental triggers and catalysts that are induced by the ventricular dysfunction, and medical therapy used in treatment (Fig 1) . An understanding of normal electrophysiology (EP) and the electrophysiological basis for ventricular dysrhythmias in HF will enhance comprehension of therapeutic measures that can prevent or treat their occurrence and potentially prevent lethal rhythm disorders.
Normal Electrophysiology
The action potential represents a change in electrical activity along the cell membrane. Each ventricular cardiac cell has 5 phases of action potential as the impulse is activated throughout the His-Purkinge conduction system. Normal action potential that generates normal rhythmic activity is based on an orderly sequence of sodium, potassium, and calcium currents in and out of cardiac cells because of changes in permeability of the membrane to these electrolytes. At rest, the inside and the outside of the ventricular cardiac cells have different voltages. The inside of the cell has a negative transmembrane resting potential of -70 to -90 mV, compared to the extracellular space.
During depolarization, known as phase 0 and represented by the QRS complex on an electrocardiogram, there is a large increase in the permeability of the membrane to sodium. Sodium lowers the resting electrical potential and the inside of the cell becomes positively charged. When depolarization ends, the transmembrane voltage is +30 mV. During phase 1 or early repolarization, the sodium channel closes and inward sodium current ceases. The transmembrane voltage is +10 to +20 mV. During phase 2 or the plateau phase, the rate of change in transmembrane voltage is slow because of a balance between sodium (already in cell) and inward calcium. During the plateau phase, represented by the ST segment, the transmembrane voltage is maintained at +10 to 0 mV. Phase 3 or repolarization is represented by the T wave and is the result of outward current of potassium from the cell, causing the ionic charge to return to its resting state of -90 mV. Phase 4 corresponds to the isoelectric line on an electrocardiogram. During phase 4, the resting potential state, the heart is in diastole and the cardiac electrical cells maintain a transmembrane resting potential of -70 to -90 mV. In phase 4, the cell membrane is normally impermeable to sodium ions and freely permeable to potassium ions. Thus potassium moves from within the cell to the extracellular space to achieve a balance in potassium ion concentration on both sides of the cell membrane. 13 Cardiac cells have 3 properties that influence electrophysiological changes: automaticity, excitability, and refractoriness. Through the properties of automaticity and excitability, ventricular cardiac cells can spontaneously depolarize, even though most cells depolarize only after a stimulus is applied to them. Once the transmembrane voltage during normal phase 3 repolarization reaches -60 to -70 mV, the cells are permeable to sodium. If sodium enters the cell during late repolarization or during the resting potential state (phase 4), the cell becomes less negatively charged and depolarizes spontaneously. Thus, the refractoriness of cardiac electrical cells to a stimulus or spontaneous depolarization is based on the level of transmembrane voltage. The absolute refractory period and effective refractory periods represent periods when cells cannot accept any stimulus regardless of intensity. This happens when the transmembrane resting potential is above the threshold potential of -60 mV. The relative refractory period of repolarization occurs during late phase 3 as potassium continues to move outward and cells become more negative. A strong stimulus or a weak stimulus with delayed conduction can initiate an impulse. The supernormal refractory period occurs at the end of phase 3 of repolarization as the transmembrane resting potential reaches -90 mV. During this period, even a weak stimulus can initiate an impulse. 13, 14 Abnormal rhythmic activity that leads to clinically relevant ventricular dysrhythmias in patients with HF can be divided into three broad categories: afterpotentials (early and delayed afterdepolarizations), reentry, and enhanced automaticity. 3, 4, 14 Each will be discussed briefly below.
Afterpotentials as a Cellular Mechanism of Ventricular Dysrhythmias
Afterpotentials are caused by an imbalance in the net inward and outward electrical current so that an abnormal amount of net inward depolarizing current affects the normal course of phase 3, repolarization, or phase 4, the resting potential state.
14 There are 2 types of afterpotentials, early afterdepolarizations and delayed afterdepolarizations. Early afterdepolarizations interrupt the normal course of phase 3 repolarization. They occur when the outward repolarizing current, potassium, is reduced or when there is an increase in inward depolarizing current of calcium (during phase 2-the plateau phase) or sodium (during phase 0 when there is an intense inward current). Early afterdepolarizations can be generated with activation of the electrogenic sodium-calcium exchange system in the sarcolemma due to high levels of myoplasmic calcium during diastole and inward pumping of sodium from the exchange system. In addition, early afterdepolarizations can be generated with activation of the sodium-potassium exchange pump. 14, 15 Triggered ventricular dysrhythmias can arise from an early afterdepolarization, especially when a net inward current develops during the plateau or early repolarization period. The mechanisms responsible for the ionic current are unknown but are believed to be due to L-type calcium channel inward current that is reactivated by prolonged depolarization. 14, 16 In addition, torsades de pointes is generally caused by triggered early afterdepolarizations (Fig 1) . In patients with HF, the occurrence of torsades can be problematic since nearly 10% of all inhospital cardiac arrests were due to this polymorphic ventricular tachycardia. 3 Delayed afterdepolarizations occur when conditions are present that cause a rise in myoplasmic calcium above normal levels during diastole (after repolarization, in phase 4 of the action potential).
14 A transient inward current of calcium can be induced by digitalis intoxication, myocardial ischemia, hypokalemia, ␤-adrenergic agonists, fast heart rate, and elevated catecholamines. Delayed afterdepolarizations can also occur from reduced resting potassium conductance from hypokalemia and other drugs. In addition, stretching of myocardial cells during ventricular remodeling has been thought to contribute to a stretch-activated inward current of calcium from the sarcoplasmic reticulum, stretchinduced activation of an inward current, or stretchinduced inactivation of outward current of standard ionic channels.
14 Ultimately, in patients with HF, failing myocytes are more susceptible to develop delayed afterdepolarizations that can generate triggered activity in the presence of conditions that induce a rise in myoplasmic calcium.
Reentry
Reentry occurs when an impulse returns to excite previously activated myocardial cells that have already been repolarized and are in phase 4 or the resting potential state.
14 Localized areas of prolonged depolarization that have areas of conduction delay or block can provide a basis for the development of reentry. At one time, reentry was thought to be a probable mechanism for ventricular dysrhythmias, but the experimental evidence was limited.
14 In recent years, electroanatomic scar mapping identified reentry as the major mechanism of dysrhythmogenesis causing sustained monomorphic ventricular tachycardia after myocardial infarction 3, 17 and also in dilated cardiomyopathy. 18 In the United States, the etiology of HF in 60% to 70% of people is due to coronary artery disease. 19, 20 Of those cases, 20% to 30% had a myocardial infarction. Therefore, postmyocardial infarction monomorphic ventricular tachycardia is an important problem that needs to be assessed, suppressed, and prevented when possible.
After myocardial infarction, left-ventricular remodeling and cellular changes are triggers for ventricular dysrhythmias. In a study that assessed the relation between left-ventricular remodeling and ventricular dysrhythmias, patients with altered leftventricular geometry (increased diastolic and systolic cavity size) had significantly more premature ventricular contractions and ventricular tachycardia at 1 and 2 years postmyocardial infarction. 21 Researchers believed that ventricular dysrhythmias in remodeled ventricles were due to reentry from slow impulse propagation velocities in the myocardium partially replaced by fibrosis. 21 After the acute phase postmyocardial infarction, fibrosis creates areas of conduction block. In addition, there is a slowing of conduction through myocyte pathways where viable myocardium and scar tissue are interlaced. 3, 17 Pathways of viable subendocardial myocardium are usually found in the border zone and can support stable reentry circuits. An appropriate trigger, such as a change in sinus rate or a premature depolarization, can lead to monomorphic ventricular tachycardia. 17 Reentry circuits in postmyocardial infarction scar can be large and extend over several centimeters. 22 Fifty percent of the time, reentry occurs in intramural tissue; less commonly, it can be confined to the epicardium. When in the epicardium, the reentry wavefront circulates around an area of fixed (due to scar) or functional conduction block. 3 No matter if sustained monomorphic ventricular tachycardia was due to reentry or another mechanism, it can be durable, recurring up to 15 years after initial myocardial infarction presentation. 3 In postmyocardial infarction patients with HF and without history of spontaneous ventricular tachycardia, ventricular tachycardia was reproducibly inducible in the majority of patients up to 6 years after myocardial infarction. 23 These findings support a heightened awareness of the need for aggressive therapy to optimize long-term outcomes.
Enhanced Automaticity
Focal automaticity accounts for approximately 27% of induced monomorphic ventricular tachycardia in nonischemic cardiomyopathy and it can also be the cause for dysrhythmias after myocardial infarction. 3 In ventricular dysrhythmias, it refers to an accelerated discharge rate of the His-Purkinge system. In general, these pacemaker cells are suppressed by the normally faster pacemaking activity of the sinus or atrioventricular nodes. In addition, ventricular muscles are resistant to developing automaticity at normal levels of diastolic potential. However, under pathological conditions, the rate of discharge of HisPurkinge pacemaker sites can be enhanced by an increase in pacemaker current, a decrease in outward potassium current during phase 4 resting potential state, or a combination of those two changes. 3 Two examples of conditions that enhance automaticity are hypokalemia, which decreases outward potassium current, and ␤-adrenergic catecholamines (or intravenous inotropic agent administration), which accelerates pacemaker activity. 3 It is known that endothelin-1, a potent cardiovascular peptide that causes vasoconstriction, is significantly associated with premature ventricular contractions, nonsustained and sustained monomorphic ventricular tachycardia in decompensated HF. 24 It is unknown if this relationship reflects a direct interaction between endothelin-1 and dysrhythmogenic mechanisms, but it is believed that its potent vasoconstrictor action may lead to dysrhythmogenesis. 24 
Other Mechanisms
There are other mechanisms of ventricular dysrhythmias that lead to SCD but that were not placed in Figure 1 . Anger and physical activity triggered ventricular dysrhythmias in a study of 277 patients with implantable cardioverter-defibrillators (ICDs) 25 ; thus, the body's response to some stressors can trigger ventricular dysrhythmias. Proarrhythmia occurring from antidysrhythmic agents or illicit drugs (cocaine) and idiopathic and inherited syndromes can lead to ventricular dysrhythmias. 26 Cardiac channel gene mutations and mutations in the cardiac ryanodine receptor calcium channel gene have been identified as causing inherited tachycardia. 26 Through research, the understanding of stressor response and molecular SCD susceptibility will increase and promote new approaches for reducing mortality risk.
In summary, patients with HF have multiple underlying mechanisms that may predispose them to developing ventricular dysrhythmias. In addition, healthcare providers may increase the risk by misusing core HF medications, not monitoring patients frequently enough for pharmacologic therapy side effects (ie, electrolyte imbalances), or failing to assess patients properly for signs and symptoms that could signify new onset ventricular dysrhythmias. As HF worsens, dysrhythmogenesis risk increases and may lead to SCD.
Prognostic Indicators
Multiple analyses of characteristics of ventricular dysrhythmias and patient characteristics have unsuccessfully identified dependable predictors of SCD. 27 The signal-averaged electrocardiogram detects the presence of late ventricular action potentials but has a poor predictive value for SCD. 27 Heart rate variability during normal sinus rhythm reflects the influence of vagal tone, which is believed to have a beneficial effect on the electrophysiologic properties of the left ventricle and the triggering of ventricular dysrhythmias. It predicts total mortality but not SCD. 27 B-type natriuretic peptide predicts SCD but the cutoff point was only 130 pg/mL in a study of 452 patients with chronic HF. 28 Since the cutoff point Ventricular Dysrhythmias in Heart Failure S15 S16 There are other challenges that make diagnosing SCD mortality risk problematic. Programmed ventricular stimulation varies with the type of underlying structural disease; in nonischemic cardiomyopathy its predictive value is low for dysrhythmic mortality, but in ischemic cardiomyopathy, predictive value for SCD is high. 29, 30 A trial that aimed to determine the benefits of ICD therapy in patients with NYHA functional classes II to III and nonischemic dilated cardiomyopathy was stopped early when a blind analysis found that the 1-year mortality was only 5.6%, compared to the pretrial estimate of 30%. The low mortality made further study enrollment futile. After mean follow-up of 5.5 years for those who had enrolled, mortality was similar in ICD and control group patients. 31 Further, there are no data that specify that pharmacologic and nonpharmacologic therapies reduce the risk of SCD on the basis of characteristics of spontaneous nonsustained ventricular dysrhythmias in patients with HF. 27 Patients may be asymptomatic, have symptoms of worsening HF due to poor stroke volume and cardiac output (lightheadedness, dizziness, or syncope), or have signs related to the tachycardia (racing heart or palpitations). Patients with HF were more likely to present with syncope, regardless of the ventricular heart rate of their ventricular tachycardia. 32 Thus, syncope, especially when it is unexplained, identifies patients with HF who are at greater risk for ventricular tachycardia and SCD, and is the single most important piece of clinical data for determining SCD risk. 3 Ultimately, healthcare providers are forced to decide who should be treated for ventricular dysrhythmias and what is the best available treatment.
Evidenced-based Management of Ventricular Dysrhythmias in Heart Failure
Patients with HF have wide variability in occurrence of ventricular dysrhythmias. Sustained monomorphic ventricular tachycardia occurs in 0.5% of patients with nonischemic HF referred for cardiac transplantation and 7% in those with ischemic HF. 4 Sustained polymorphic ventricular tachycardia is unstable compared to monomorphic ventricular tachycardia and is likely to cause torsades de pointes when QT prolongation is present, cause ischemia and infarction, and degenerate into ventricular fibrillation. 4 Some patients may be receiving medications with antidysrhythmic or arrhythmogenic properties as core treatment for HF. These agents can modify the natural occurrence of ventricular dysrhythmias and need to be understood on the basis of their effects on ventricular dysrhythmia modification.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Angiotensin-converting enzyme inhibitor (ACE-I) therapy is the cornerstone of core HF therapy. It prolongs life, decreases morbidity, improves ejection fraction, and attenuates ventricular remodeling. While many studies have assessed all-cause mortality and cardiovascular mortality, few have reported the prevalence of ventricular tachycardia and SCD as outcomes.
The V-HeFT II investigators reported a 27% reduction in ventricular tachycardia prevalence (P < .02) at 1 year in the enalapril group compared to patients treated in the hydralazine-isosorbide dinitrate group. Using Holter monitor electrocardiograms, they reported that ACE-I therapy decreased the persistence of baseline ventricular tachycardia at 3 months and the emergence of new ventricular tachycardia at 1 and 2 years. 33 In addition, the reduction in ventricular dysrhythmias paralleled the reduction in SCD. The V-HeFT investigators postulated that the improved results were due to improved leftventricular function and/or less rise in plasma norepinephrine in the enalapril-treated patients. 6, 33 The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) evaluated the effects of enalapril or placebo on mortality in severe HF. In this study, cardiac and total mortality were significantly improved in the enalapril group when compared to the placebo group; however, SCD (defined as death within 1 hour of new symptoms) and cardiac death within 24 hours of new symptoms were not significantly different between groups. 34 It is unknown if the lack of benefit was due to the severe HF itself or comorbidities associated with severe HF, such as renal dysfunction and hypotension. The Studies of Left Ventricular Dysfunction 20 investigators also assessed cause of death when comparing results between patients assigned to enalapril or placebo. All-cause death was significantly improved in patients randomized to enalapril and there was also a 10% risk reduction in death due to dysrhythmia without worsening HF; however, this trend did not reach significance. 35 Angiotensin receptor blockers are the alternative to ACE-I therapy when contraindications prevent ACE-I therapy. In studies that provided evidence of the effectiveness of using losartan and valsartan as an alternative to ACE-I due to nontolerance, investigators did not demonstrate a significant reduction of SCD with the treatment agents. 36, 37 Thus, while ACE-I and ARB therapy reduced total mortality in many trials, ARB therapy did not appear to confer antidysrhythmic or SCD reduction benefit and ACE-I therapy appeared to reduce susceptibility to ventricular dysrhythmias and SCD for some of the patients studied.
Whether or not ACE-I and ARB therapies are actually beneficial or are neutral in ventricular dysrhythmia incidence, all patients should be on one of these vasodilators as a core HF pharmacologic therapy, unless contraindicated. Nurses should promote drug utilization and proper dosing based on recommendations from large trial experiences.
Both ACE-I and ARB increase the serum potassium level since serum potassium is negatively correlated with plasma renin and noradrenaline. As HF improves with drug therapy, intracellular potassium concentrations increase. 38 Nurses must assess serum potassium levels when agents are initiated or withdrawn and when drug dosage is increased or decreased to ensure an optimized serum potassium level, especially if potassium supplements and dietary potassium are discouraged because of a fear of hyperkalemia. A serum potassium level of 4.4 mmol/L or less is associated with SCD. 38 An ideal serum potassium level in patients with HF is 4.5 to 5.5 mmol/L. 38 Thus, nursing care includes educating patients about the need to maintain a serum potassium level in the proper range by making appropriate modifications in diet and/or drug therapies or restrictions to ensure the lowest risk for new onset or worsening ventricular dysrhythmias that could be fatal.
Beta Blockers
In the United States, metoprolol-controlled release/ extended release, bisoprolol, and carvedilol are approved beta blockers for use in patients with HF, despite functional class. As with ACE-I and ARB therapy, beta blocker therapy reduced total mortality in large, randomized, placebo-controlled trials; however, not all investigators demonstrated a reduced SCD rate. In the Multicenter Unsustained Tachycardia Trial of 2096 patients with ischemic HF and a history of nonsustained ventricular tachycardia, beta blockers were beneficial in reducing total mortality and also dysrhythmic death or cardiac arrest. However, after adjustment for demographic and medical history variables, event rates were not significantly lowered in patients treated with beta blockers. 39 The Multicenter Unsustained Tachycardia Trial study had limitations. It was not designed to test the efficacy of beta blocker therapy; referring physicians chose to use this therapy at their discretion. Nevertheless, results of this study were similar to findings from the AVID trial in which beta blockers were not associated with improved survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia. 40 Other researchers found beta blockers to be beneficial for patients with ventricular dysrhythmias. In MERIT-HF, patients with functional classes II to IV HF had a significant risk reduction for SCD in the metoprolol-controlled release/extended release group (41% overall) compared to placebo and in hypertensive patients, the risk reduction for SCD was greater (49%). 7, 41 In 3 large placebo-controlled studies of carvedilol, two that enrolled patients with mild to moderate HF (Multicenter Oral Carvedilol Heart Failure Assessment and U.S. Carvedilol Heart Failure Study Group) and one that enrolled patients after acute myocardial infarction and left-ventricular dysfunction (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction), carvedilol reduced SCD events. [42] [43] [44] In patients with advanced HF evaluated for heart transplant, patients on both ACE-I and beta blocker therapy had significantly less SCD than did those on ACE-I alone. 45 The Studies of Left Ventricular Dysfunction investigators compared mortality depending on beta blocker usage and found that in both the prevention and treatment trials, beta blocker therapy significantly reduced dysrhythmic deaths. 46 In a study of nesiritide and dobutamine therapies in acutely decompensated patients with HF requiring hospitalization, 24-hour Holter recordings were used to assess dysrhythmias. Concurrent beta blocker therapy was associated with less premature ventricular beats, couplets, and repetitive premature ventricular beats per hour, and less ventricular tachycardia per 24 hours. After adjustment for clinical variables and other drug therapies, age, amiodarone use, and plasma potassium level were also significantly associated with ventricular dysrhythmia suppression. 47 Researchers believed that beta blocker therapy effectiveness in preventing serious ventricular dysrhythmias might be important during transient increases in sympathetic nervous system activity. Beta blockers have an antifibrillatory effect that might also play a role in the reduction in SCD. 48 Thus, it is widely recognized that beta blocker therapies slow heart rate and are associated with reduced ventricular dysrhythmogenesis in patients with HF. Patients benefit despite their clinical condition at study entry. However, SCD event rates may only be reduced in some patients on beta blockers, signaling the need for ICD therapy in patients with a history of syncope or other signs of high risk for lethal ventricular dysrhythmias (Table 1) . Nurses should ensure patients are on a Food and Drug Administration-approved beta blocker for use in HF and should uptitrate the dose slowly over many weeks to achieve target dosing per drug manufacturer. Symptomatic hypotension (with third-class beta blockers like carvedilol) and bradycardia must be assessed; however, it may not be necessary to discontinue beta blockers in these patients if symptoms occur. Rather, it might be necessary to reassess all drug therapies for administration timing. Altering beta blocker administration in relation to other drug therapies might relieve symptoms and allow for continued life-saving therapy usage.
Aldosterone Antagonists
Aldosterone inhibition with spironolactone, a potassium-sparing diuretic, was shown to significantly reduce all-cause mortality and SCD in patients with advanced, decompensated HF in the Randomized Aldactone Evaluation Study. 56 Spironolactone significantly reduced ventricular dysrhythmias 57 and reduced corrected QT max and QT dispersion in patients with congestive HF. 58 In addition, in the Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, eplerenone significantly reduced all-cause mortality and SCD. 59 Specific mechanisms leading to aldosterone antagonist survival benefits are unknown. Future studies will help determine neurohumoral benefits that might confer SCD reduction. Researchers think spironolactone may prevent SCD by increasing serum potassium levels, by altering myocardial norepinephrine uptake, 60 or by shortening corrected QT interval, since prolongation has been repeatedly associated with SCD risk. 58 Current evidence suggests that aldosterone antagonists are beneficial in reducing SCD events in patients with advanced, medically refractory HF (functional classes III-IV) and postacute myocardial infarction (during initial treatment) when complicated by any degree of HF. These 2 patient populations are diverse. Research has not been conducted in patients with mild to moderate HF of nonischemic etiology. Therefore, it should not be assumed that aldosterone antagonists benefit all patients with HF. Careful selection of patients is important and should be based on HF etiology, clinical condition, and renal function. As discussed with ACE-I and ARB therapies, nurses must routinely assess serum potassium levels and educate patients regarding maintaining a balanced potassium level when using an aldosterone antagonist. Generally, a potassium level should be obtained 1 week after initiating therapy and then monitored routinely. More frequent monitoring is necessary if drug dosage is changed or the drug is withdrawn.
Digitalis, Diuretics, Intravenous Inotropic, and Intravenous Vasodilator Agents
In patients with HF, digoxin does not have any effect on mortality and on the number of patients hospitalized for ventricular dysrhythmias or for cardiac death. 61 Use of nonpotassium sparing diuretics was associated with increased risk of dysrhythmic death in many studies, 62, 63 whereas potassium-sparing diuretic led to a nonsignificant risk reduction for dysrhythmic death of 14% in one large, randomized study. 62 Potassium and magnesium depletion were considered the most likely mechanisms for fatal and nonfatal dysrhythmias. [62] [63] [64] Intravenous positive inotropic agents enhance contractility, but at the price of also increasing mortality, especially SCD from lethal ventricular dysrhythmias. 47 Diuretics and intravenous inotropic agents, both of which are used to improve hemodynamics and manage symptoms, are dysrhythmogenic and should be used only as needed and with caution. In addition, emphasis should be placed on lifestyle modifications, such as 2000-mg sodium diet and fluid monitoring/ management, that may decrease the need for extra dosing and escalation of dose of diuretics, especially in mild to moderate HF. Intravenous inotropic agents should only be administered when patients exhibit signs and symptoms of hypoperfusion in the setting of diuretic-refractory complex decompensation. They should be administered temporarily in an acute setting and are not indicated in chronic HF care except at end of life.
Nurses must assess serum potassium routinely and when digoxin and diuretic dosages are increased, decreased, or withdrawn. Hypokalemia increases ventricular dysrhythmias and is a strong independent predictor of mortality in HF. 38 Hypokalemia predisposes to digoxin toxicity by reducing renal clearance and promoting myocardial binding of digoxin that leads to increased automaticity and ventricular dysrhythmias. 38 When serum potassium levels fail to rise after supplemental potassium administration, a serum magnesium level should be drawn. Often, hypomagnesemia may prevent the serum potassium level from rising adequately.
The 3 most commonly used intravenous vasodilators in acute decompensated HF are nitroprusside, nitroglycerin, and nesiritide. Each agent has been associated with hypotension and nitrates have been associated with headache and flushing; however, no agent has been studied in a trial that has been powered for long-term effects on ventricular dysrhythmias or SCD event rates. 65 Some nesiritide researchers have assessed ventricular tachycardia. In a study that compared 2 doses of nesiritide and dobutamine in acute decompensated HF on short-term mortality, patients in the high-dose nesiritide group had significantly higher frequency of sustained ventricular tachycardia or fibrillation at baseline than did those in the lowdose nesiritide and dobutamine groups. 66 However, when ventricular tachycardia frequency was analyzed during the first 24 hours of dosing, low-dose nesiritide (0.015 mcg kg -1 min -1
) subgroup had significantly more nonsustained ventricular tachycardia but no cardiac arrest. Only dobutamine caused sustained ventricular tachycardia, resulting in a cardiac arrest (not statistically significant). 66 In another comparative study of nesiritide and dobutamine in which Holter monitoring was performed, dobutamine, but not nesiritide, led to significantly increased ventricular tachycardia, repetitive ventricular beats, and premature ventricular beats per hour. 67 Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) investigators compared nitroglycerine to nesiritide at doses approved for use today (0.01 mcg kg -1 min -1
). In this study, the VMAC investigators found no statistical difference in ventricular tachycardia or extrasystoles in the first 24 hours after start of study drug.
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Statins
Do lipid-lowering agents have antidysrhythmic properties? Investigators of the AVID trial sought to answer that question since earlier research in patients with atherosclerotic disease suggested that lipid-lowering agents reduced SCD. In AVID, using multivariate analyses, lipid-lowering therapies reduced the relative risk of ventricular tachycardia or fibrillation recurrence by 40% in the ICD subgroup. In addition, the relative risk was lowered for all-cause mortality by 36% and cardiac mortality by 39% in the larger study population. 69 In a single center cohort study of patients with advanced HF, statin use was associated with significantly less mortality in both ischemic and nonischemic cardiomyopathy. 70 A major limitation of both studies was that patients were not randomized to lipid-lowering agents. These results are hypothesis generating and need to be confirmed through a randomized, controlled study.
Collaboration among nurses, physicians, and other healthcare professionals can ensure that medication therapies are optimized. If syncope occurs, therapies must be reassessed to ensure that patients are on agents known to suppress or prevent ventricular dysrhythmias. Patient education regarding risk for ventricular dysrhythmias and SCD should be provided along with messages that give patients control (self-management behaviors) and hope to decrease the onset of emotional stress that could generate ventricular dysrhythmias.
Antiarrhythmic Pharmacologic Therapy With Amiodarone
Amiodarone is the only antidysrhythmic agent without significant proarrhythmic effects in HF patients. It has class III effects (prolongs the action potential by inhibiting outward potassium channels during phase 3 repolarization) but it also has beta blocker effects, class I effects (blocks inward sodium channel during phase 0, thus, can produce QRS prolongation), and class IV effects (blocks inward calcium channels during the plateau phase). 48 Amiodarone effectively suppresses premature ventricular contractions and nonsustained ventricular tachycardia. However, of 2 studies of its effectiveness in preventing total mortality and SCD in patients with HF, neither was able to demonstrate benefits in either endpoint. 48 In a meta-analysis of secondary prevention studies that compared amiodarone to an ICD in patients with HF (most study participants had ischemic HF; only 2 small German studies included patients with dilated HF), survival advantage consistently was seen in the ICD group, not in the amiodarone group. 71 Amiodarone is used to suppress ventricular arrhythmias in patients who do not meet the current consensus guideline recommendations for an ICD, thus improving quality of life. 72, 73 In addition, amiodarone is used in patients who have frequent ventricular dysrhythmic events (electrical storm) triggering the ICD device, to prolong VT cycle length and to increase efficiency of antitachycardia pacing. 72 Amiodarone may increase defibrillation energy requirements and alter pacing thresholds 72 ; therefore, device interrogation is needed to ensure optimal functioning.
It is essential to recognize that amiodarone does not decrease all-cause mortality nor reduce SCD. Patients may be on many drugs for HF and comorbidities. If amiodarone does not reduce the heart rate, suppress or reduce ventricular rate in atrial fibrillation, or decrease episodes and symptoms associated with nonsustained ventricular tachycardia, the healthcare team should reevaluate its use. Nurses are in a prime position to make recommendations that could decrease polypharmacy and cost of care. Developing a collaborative model of practice or care partnering with physicians can advance patient care and may improve quality of life and clinical outcomes.
Device Therapy With ICDs
As stated earlier, in secondary prevention studies, ICD therapy was superior to amiodarone. In another secondary prevention study to determine who was most likely to benefit from ICD placement, researchers concluded that those aged 70 or over, those with an ejection fraction of 35% or less, and those in NYHA functional class III or IV had the highest risk of death and benefited the most. 74 In primary prevention studies of SCD in medically managed patients with HF, ICD use led to survival advantage compared to antidysrhythmic drug therapy and/or standard medical therapies. Table 1 contains a synopsis of recent studies that form the research base of current ICD consensus guidelines (refer to the first 3 studies). 72, 75 It also includes recently presented and published studies that will affect guideline revisions (expected to be released in 2004) of ICD usage in patients with HF.
When patients are hospitalized, nurses are often the gatekeepers to antidysrhythmic drug and device therapies since patients often receive electrocardiographic monitoring. Patients should receive an EP consult when criteria set up by national cardiology organizations in written consensus recommendations 72, 75 are met. An acute decompensation episode that results in hospitalization often provides the perfect opportunity for thorough assessment and management of ventricular dysrhythmias.
Electrophysiology Study and Ablation
The role of EP study (ventricular-programmed stimulation) in patients with HF and ventricular dysrhythmias is not clearly defined. Some physicians believe that an EP study is indicated in patients with ischemic cardiomyopathy and a history of sustained monomorphic VT or those at high risk of SCD as a way to risk stratify ventricular dysrhythmias and optimize the pharmacologic approach. 76 However, recent primary prevention ICD studies, all of which were conducted without an EP study and all of which promoted optimized core HF therapies (ACE-I, beta blocker, and aldosterone inhibitor therapies as appropriate), showed that ICD device therapy improved survival regardless of the patient's history of ventricular dysrhythmias, risk of SCD, or pharmacologic therapy at study enrollment. In dilated cardiomyopathy, risk stratification and pharmacologic management via EP study is even more controversial. 76 Ventricular dysrhythmogenic mechanisms are heterogeneous, the response to programmed stimulation varies on the basis of the dysrhythmogenic mechanism and in patients who have survived an episode of cardiac arrest, VT may not be induced with programmed stimulation, even though these patients are known to be at higher risk for SCD. 76 After reviewing newer results from ICD studies in patients with HF from nonischemic and ischemic cardiomyopathy, it appears that functional class and ejection fraction may be the primary determinants of risk in this patient population. Future research should focus on clinical, economical, and organizational issues of EP study to clarify its role in patients with ventricular dysrhythmias. Generally, patients may require an EP study to determine if ventricular radiofrequency ablation is an appropriate therapy. Patients at high risk for SCD when standard therapies are refractory (amiodarone and ICD therapy) may derive the greatest benefit. To facilitate optimal consultation, questions to ask in patients already receiving standard medical therapies for ventricular dysrhythmias are as follows: (a) Has the patient had a cardiac arrest due to VT or VF not due to a transient cause? (b) Does the patient have an LVEF ≤ 30% and MI > 1 month ago or CABG > 3 months ago? (c) Has the patient had syncope, spontaneous sustained VT or nonsustained VT? Ventricular radiofrequency catheter ablation therapy is evolving. It can eliminate ventricular dysrhythmias in 70% to 100% of cases and has a low complication rate of 1% to 2%. 77 When the electrophysiologist performs ventricular-programmed stimulation and finds a focal origin, ablation is facilitated. Challenges arise when there are multiple ventricular tachycardia sites or reentry paths. 77 
Conclusion
In patients with HF, ventricular dysrhythmias are a comorbidity that may require unique medical therapies that may include an antidysrhythmic agent, ICD device, and possibly catheter ablation. In addition, ventricular dysrhythmias can be viewed as an extension of HF; when HF becomes a clinical syndrome (functional class II or greater), the risk for ventricular dysrhythmias rises. In this view, it is imperative that nurses and other healthcare providers understand consensus recommendations for core pharmacologic therapies, even when the patient is asymptomatic, so that medications are appropriately applied to prevent or suppress ventricular dysrhythmias. Outcomes can be optimized by applying our understanding of pharmacologic and nonpharmacologic HF therapies to promote use of those therapies known to decrease risk of SCD, such as administering beta blockers and aldosterone antagonists at the right doses; diet, medication, and lab monitoring to maintain a serum potassium level in the optimum range; and an ICD device. Nurses are key to assessing patients for SCD risk, educating patients about sensations and symptoms that require contact with healthcare providers, and effectively communicating patient therapy needs to healthcare team members who can act on patient issues. Currently, the only "cure" for ventricular dysrhythmias is radiofrequency catheter ablation. This therapy is still in its infancy but offers hope of a better future for patients who have psychological and social distress from ICD firings or who have emotional stress from worrying that they may have an SCD event at any time.
